Sintx Technologies, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
SINT$1.56-3.7%Stored close · as of Nov 6, 2026
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2026-06-30; filed 2026-08-11.
0001493152-26-037116
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2026-09-30; filed 2026-11-05.
0001493152-26-050221
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 73 previous paragraphs and 73 current paragraphs.
41 unchanged; 26 reworded; 6 added; 5 removed; 1 previous and 0 current paragraphs rearranged.
Tables are not compared: 2 previous and 2 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (6)
Current report
For the nine months ended September 30, 2026, general and administrative expenses increased by $2.3 million, or 47%, compared to the same period in 2025. The increase was primarily due to approximately $2.1 million in overhead costs reallocated from research and development to general and administrative expenses, reflecting the Company’s continued shift toward commercialization. Additionally, employee-related costs increased by $1.1 million. These increases were partially offset by $0.9 million in additional overhead costs allocated to inventory in connection with increased manufacturing activities.
Current report
For the three months ended September 30, 2026, grant and contract expenses increased by $35,000, or 152%, compared to the same period in 2025, primarily due to the increase in grant and contract revenue.
Current report
We continue to pursue initiatives intended to strengthen our financial position through increased commercial activity, improved operating efficiencies, and disciplined cost management. Our OEM technical manufacturing operations remain an important source of revenue and cash flow, with increased customer demand, pricing improvements, and higher production volumes contributing to improved operating performance during 2026. Management expects continued demand for our OEM products at levels above those experienced in prior periods, although quarterly sales volumes may fluctuate based on the timing and size of customer orders. We also continue to advance the commercialization of our proprietary silicon nitride-based medical technologies, including the SiNAPTIC Foot & Ankle Osteotomy Wedge System, which received FDA 510(k) clearance in October 2025 and generated initial commercial revenue during 2026. Future revenue from these products will depend on physician adoption, customer demand, distributor performance, manufacturing capacity, and market conditions.
Current report
Inventory increased from approximately $1.0 million at December 31, 2025 to $2.6 million at September 30, 2026, primarily reflecting increased finished goods inventory to support the commercial launch of our SiNAPTIC medical devices, as well as production to fulfill existing OEM customer purchase orders. The increase represents a strategic investment in working capital to support our expanding commercialization and manufacturing activities.
Current report
In September 2026, we entered into an accounts receivable factoring arrangement and sold a trade receivable with a face amount of approximately $1.7 million. We received approximately $1.5 million in cash and expect to receive approximately $0.2 million in deferred purchase price upon collection, subject to contractual adjustments. The deferred purchase price was recorded at its estimated fair value based on expected collections, customer credit risk and payment history. The transaction was accounted for as a sale, resulting in a loss of approximately $37,000, primarily related to transaction fees. The arrangement is generally nonrecourse for customer credit losses, although we may be required to repurchase the receivable in the event of customer disputes or breaches of representations and warranties. We also retain certain obligations related to customer disputes and remittance of collections received directly. We may utilize similar arrangements in the future to support working capital requirements.
Current report
Subsequent to September 30, 2026, we received aggregate gross proceeds of approximately $2.0 million from the exercise of certain Class B Common Stock Purchase Warrants following the exercise of our warrant call rights in October 2026. The proceeds provide additional capital to support our ongoing operations and working capital requirements. Following the completion of the warrant call, no Class B warrants remain outstanding.
Removed paragraphs (5)
Previous report
For the three months ended June 30, 2026, general and administrative expenses increased by $0.9 million, or 64%, compared to the same period in 2025. The increase was primarily due to $0.8 million in higher headcount-related costs, including $0.1 million of non-cash stock-based compensation, as well as the reallocation of certain overhead costs of $0.7 million, as discussed above. These increases were partially offset by decreases of $0.2 million in board of directors fees, $0.1 million in non-employee stock-based compensation, $0.1 million in accounting fees, and $0.2 million in other general expenses.
Previous report
For the six months ended June 30, 2026, grant and contract expenses decreased by $44,000, or 44%, compared to the same period in 2025, primarily due to the decrease in grant and contract revenue.
Previous report
The board of directors and management remain aligned in advancing the Company’s strategic direction and business objectives. While we expect to continue generating a significant portion of our revenues from our industrial business product line, management is increasingly concentrating resources on high-growth areas within the healthcare sector where our proprietary materials and technologies—such as silicon nitride—provide a distinct competitive advantage due to their unique strength, durability, and biocompatibility. We believe our established industrial activities provide an important operational and revenue foundation that supports the continued development and commercialization of our medical technologies. Building upon our established advanced materials expertise and FDA 510(k) clearance of the SiNAPTIC Foot & Ankle Osteotomy Wedge System, we are focused on commercializing our medical technologies and advancing additional silicon nitride-based compositions and applications for orthopedic, spinal, wound care, and other medical markets in order to expand our footprint in the medical device sector and support creation of long-term shareholder value.
Previous report
As part of our ongoing strategic review of our operations aimed at improving operational efficiency and reducing costs, as discussed in Note 2 to the condensed consolidated financial statements, on February 19, 2025, we sold to Tethon all the issued and outstanding shares of TA&T in exchange for the assumption by Tethon of the outstanding liabilities of TA&T.
Previous report
As discussed in further detail above, in October 2025, we received FDA 510(k) clearance for a new foot and ankle osteotomy wedge system, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. We recognized initial revenue from the system during the first and second quarters of 2026. The timing and amount of future revenue will depend on, among other matters, physician adoption, customer ordering patterns, distributor performance, manufacturing capacity and reimbursement and market conditions.
Reworded paragraphs (26)
Previous wording
The following is a tabular presentation of our unaudited condensed consolidated operating results for the three and six months ended June 30, 2026 and 2025 (in thousands):
Current wording
The following is a tabular presentation of our unaudited condensed consolidated operating results for the three and nine months ended September 30, 2026 and 2025 (in thousands):
Previous wording
For the three months ended June 30, 2026, total revenue increased $0.3 million, or 199%, compared to the same period in 2025. For the six months ended June 30, 2026, total revenue increased $0.3 million, or 60%, compared to the same period in 2025. When excluding the total revenue decrease of $0.1 million due to the sale of the TA&T subsidiary, the remaining total revenue for the six months ended June 30, 2026 increased by $0.4 million, or 102%.
Current wording
For the three months ended September 30, 2026, total revenue increased $2.0 million, or 953%, compared to the same period in 2025. For the nine months ended September 30, 2026, total revenue increased $2.3 million, or 315%, compared to the same period in 2025.
Previous wording
For the three months ended June 30, 2026, product revenue increased $0.3 million, or 347%, compared to the same period in 2025. For the six months ended June 30, 2026, product revenue increased $0.4 million, or 91%, compared to the same period in 2025. When excluding the product revenue decrease of $0.1 million due to the sale of the TA&T subsidiary, the remaining product revenue for the six months ended June 30, 2026 increased by $0.4 million, or 128%.
Current wording
For the three months ended September 30, 2026, product revenue increased $1.9 million, or 1,293%, compared to the same period in 2025. For the nine months ended September 30, 2026, product revenue increased $2.3 million, or 424%, compared to the same period in 2025.
Previous wording
During the three months ended June 30, 2026, grant and contract revenue decreased $46,000, or 90%, as compared to the same period in 2025. During the six months ended June 30, 2026, grant and contract revenue decreased $44,000, or 34%, as compared to the same period in 2025. When excluding the grant and contract revenue decrease of $45,000 due to the sale of the TA&T subsidiary, the remaining grant and contract revenue for the six months ended June 30, 2026 increased by $1,000, or 1%.
Current wording
During the three months ended September 30, 2026, grant and contract revenue increased $42,000, or 72%, as compared to the same period in 2025. During the nine months ended September 30, 2026, grant and contract revenue decreased $2,000, or 1%, as compared to the same period in 2025.
Previous wording
Total revenue increased compared with the prior-year periods, primarily reflecting higher product sales from the Company’s operations. Comparability to the prior year was also affected by the divestiture of the TA&T subsidiary during the first quarter of 2025.
Current wording
Total revenue increased significantly compared with the prior-year periods, primarily reflecting higher product sales from the Company's OEM technical manufacturing operations.
Previous wording
Product revenue growth was driven primarily by increased sales within the Company’s OEM technical manufacturing products, reflecting improved customer demand and pricing, together with initial commercial sales of the SiNAPTIC Foot & Ankle Osteotomy Wedge System. These increases were partially offset by lower grant and contract revenue, which can fluctuate based on the timing and scope of funded projects.
Current wording
Product revenue growth was driven primarily by increased sales volumes, including a significant order from a major OEM customer, as well as pricing initiatives implemented during 2026. While the timing and volume of customer orders may result in fluctuations in quarterly revenue, the Company continues to focus on strengthening customer relationships and expanding its OEM manufacturing activities. Revenue growth also benefited from initial commercial sales of the SiNAPTIC Foot & Ankle Osteotomy Wedge System, reflecting continued progress in the commercialization of the Company's proprietary silicon nitride-based medical devices. Grant and contract revenue remained relatively consistent for the nine-month period, although revenue from these activities may fluctuate based on the timing and scope of funded projects.
Previous wording
The Company continues to support its OEM technical manufacturing product line as an important source of revenue and cash flow. Recent pricing initiatives have improved the profitability of this product line while allowing the Company to continue investing in the commercialization of its proprietary silicon nitride-based biomedical devices, including its orthopedic product portfolio. Management expects the OEM product line and its proprietary medical technology initiatives to remain complementary components of the Company’s long-term growth strategy.
Current wording
The Company continues to support its OEM technical manufacturing operations as an important source of revenue and cash flow. Recent pricing initiatives, together with increased sales volumes, have contributed to improved gross margins while allowing the Company to continue investing in the commercialization of its proprietary silicon nitride-based biomedical devices, including its orthopedic product portfolio. Management expects its OEM manufacturing operations and proprietary medical technology initiatives to remain complementary components of the Company's long-term growth strategy.
Previous wording
For the three months ended June 30, 2026, cost of revenue increased by $0.1 million, or 85%, compared to the same period in 2025. For the six months ended June 30, 2026, cost of revenue increased by $0.1 million, or 21%, compared to the same period in 2025. Cost of revenue increased at a lower rate than revenue primarily due to the Company’s continued focus on higher-margin sales and a favorable sales mix, with improved pricing on certain OEM products, during the current period. Although the Company expects this strategy to continue to support profitability, gross margin may fluctuate from period to period based on product mix, pricing, manufacturing efficiencies, customer demand, and the mix of product and grant and contract revenue.
Current wording
For the three months ended September 30, 2026, cost of revenue increased by $0.7 million, or 620%, compared to the same period in 2025. For the nine months ended September 30, 2026, cost of revenue increased by $0.8 million, or 172%, compared to the same period in 2025. Cost of revenue increased at a lower rate than revenue primarily due to improved pricing on certain OEM products, increased sales volumes resulting in better absorption of fixed manufacturing costs and improved production efficiencies, and a favorable product mix. These factors contributed to improved gross margins during the current periods. While the Company expects its pricing initiatives and continued focus on higher-margin sales to support profitability, gross margins may fluctuate from period to period based on product mix, pricing, manufacturing efficiencies, customer demand, and the mix of product and grant and contract revenue.
Previous wording
For the three months ended June 30, 2026, research and development expenses decreased by $0.7 million, or 54%, compared to the same period in 2025. The decrease was primarily due to $0.7 million in the reallocation of certain overhead costs to general and administrative expenses (also see explanation below). Other research and development expenses remained consistent during the period.
Current wording
For the three months ended September 30, 2026, research and development expenses decreased by $0.7 million, or 57%, compared to the same period in 2025. The decrease was primarily attributable to the reallocation of approximately $0.7 million in overhead costs from research and development to general and administrative expenses, as further discussed below. Other research and development expenses remained relatively consistent during the period.
Previous wording
For the six months ended June 30, 2026, research and development expenses decreased by $1.4 million, or 60%, compared to the same period in 2025. The decrease was primarily due to $1.4 million in the reallocation of certain overhead costs to general and administrative expenses (also see explanation below). Other research and development expenses remained consistent during the period.
Current wording
For the nine months ended September 30, 2026, research and development expenses decreased by $2.1 million, or 59%, compared to the same period in 2025. The decrease was primarily attributable to the reallocation of approximately $2.1 million in overhead costs from research and development to general and administrative expenses. Other research and development expenses remained relatively consistent during the period.
Previous wording
Historically, a significant portion of our operations was focused on research and development, resulting in the majority of overhead costs being allocated to research and development. As our focus has shifted toward commercialization, a greater portion of these costs is now classified as general and administrative.
Current wording
Historically, a significant portion of the Company’s operations was focused on research and development, resulting in a substantial portion of overhead costs being allocated to research and development expenses. As the Company has increasingly shifted its operational focus toward commercialization, the allocation of overhead costs has been adjusted to better reflect the nature of the activities being supported. Consequently, a greater portion of these costs is now classified as general and administrative expenses.
Previous wording
For the six months ended June 30, 2026, general and administrative expenses increased by $2.1 million, or 78%, compared to the same period in 2025. The increase was primarily due to $1.1 million in higher headcount-related costs, including $0.5 million of non-cash stock-based compensation, as well as the reallocation of certain overhead costs of $1.4 million, as discussed above, and $0.1 million in other general expenses. These increases were partially offset by decreases of $0.3 million in non-employee stock-based compensation and $0.2 million in board of directors fees.
Current wording
For the three months ended September 30, 2026, general and administrative expenses increased by $0.1 million, or 7%, compared to the same period in 2025. The increase was primarily due to approximately $0.7 million in overhead costs reallocated from research and development to general and administrative expenses, reflecting the Company’s continued shift toward commercialization. The increase was partially offset by decreases of $0.3 million in non-employee stock-based compensation, $0.2 million in employee-related costs, and $0.2 million in additional overhead costs allocated to inventory in connection with increased manufacturing activities.
Previous wording
For the six months ended June 30, 2026, sales and marketing expenses increased by $0.6 million, or 1,539%, compared to the same period in 2025. The increase was primarily due to $0.3 million in higher headcount-related costs, including $0.1 million of non-cash stock-based compensation, as well as a $0.3 million increase in other sales and marketing related costs associated with our product launch.
Current wording
For the three months ended September 30, 2026, sales and marketing expenses increased by $0.1 million, or 137%, compared to the same period in 2025. The increase was primarily due to a $0.1 million increase in other sales and marketing related costs associated with our product launch.
Previous wording
For the three months ended June 30, 2026, sales and marketing expenses increased by $0.3 million, or 1,200%, compared to the same period in 2025. The increase was primarily due to $0.2 million in higher headcount-related costs, including $34,000 of non-cash stock-based compensation, as well as a $0.1 million increase in other sales and marketing related costs associated with our product launch.
Current wording
For the nine months ended September 30, 2026, sales and marketing expenses increased by $0.7 million, or 712%, compared to the same period in 2025. The increase was primarily due to $0.3 million in higher headcount-related costs, including non-cash stock-based compensation, as well as a $0.4 million increase in other sales and marketing related costs associated with our product launch.
Previous wording
For the three months ended June 30, 2026, grant and contract expenses decreased by $46,000, or 96%, compared to the same period in 2025, primarily due to the decrease in grant and contract revenue.
Current wording
For the nine months ended September 30, 2026, grant and contract expenses decreased by $9,000, or 7%, compared to the same period in 2025, primarily due to the decrease in grant and contract revenue.
Previous wording
For the three months ended June 30, 2026, other income, net decreased by $0.2 million, or 48%, compared to the same period in 2025, primarily due to a $0.4 million decrease in gain on disposal of equipment, partially offset by a $0.2 million increase from the change in value of derivative liabilities.
Current wording
For the three months ended September 30, 2026, other income, net increased by $0.2 million, or 122%, compared to the same period in 2025, primarily due to the $0.2 million change in value of derivative liabilities during 2025. There was no change in value of derivative liabilities during the third quarter of 2026.
Previous wording
For the six months ended June 30, 2026, other income, net increased by $0.1 million, or 30%, compared to the same period in 2025, primarily due to a $0.4 million increase from the change in value of derivative liabilities, partially offset by a $0.3 million decrease in gain on disposal of equipment.
Current wording
For the nine months ended September 30, 2026, other income, net increased by $0.4 million, or 139%, compared to the same period in 2025, primarily due to a $0.6 million increase from the change in value of derivative liabilities, partially offset by a $0.3 million decrease in gain on disposal of equipment.
Previous wording
The condensed consolidated financial statements have been prepared assuming we will continue to operate as a going concern. To date, our operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that we will continue to generate operating losses and use cash in operations. Our continuation as a going concern is dependent upon our ability to increase sales, decrease expenses and raise additional funding. We continue to seek opportunities to raise additional funding through equity and/or debt financing. However, such funding is not guaranteed and may not be available to us on favorable terms and may involve restrictive covenants. If we are not able to obtain additional debt or equity financing, the impact on us will be material and adverse.
Current wording
The condensed consolidated financial statements have been prepared assuming we will continue to operate as a going concern. To date, our operations have been principally financed through proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. We expect to continue incurring operating losses and using cash in operations as we advance our commercialization initiatives. Our ability to continue as a going concern depends on our ability to increase revenues, manage operating expenses, and obtain additional financing. We continue to evaluate opportunities to raise additional capital through equity and/or debt financing; however, there can be no assurance that additional funding will be available on acceptable terms, if at all. Any financing obtained may involve restrictive covenants or dilution to existing stockholders. Failure to obtain sufficient additional financing could materially adversely affect our operations and financial condition.
Previous wording
For the six months ended June 30, 2026, and 2025, we incurred a net loss of $5.5 million and $4.6 million, respectively, and used cash in operating activities of $5.3 million and $3.7 million, respectively. We had an accumulated deficit of $298 million and $292 million as of June 30, 2026, and December 31, 2025, respectively.
Current wording
For the nine months ended September 30, 2026 and 2025, we incurred net losses of $7.1 million and $8.1 million, respectively, and used cash in operating activities of $6.6 million and $6.2 million, respectively. We had an accumulated deficit of $299 million as of September 30, 2026, compared to $292 million as of December 31, 2025.
Previous wording
As discussed in Note 12 to the condensed consolidated financial statements, in October 2025, we entered into a sublease agreement to lease the SINTX Armor facility, that is expected to save us approximately $1.0 million over the sublease term.
Current wording
As part of our ongoing efforts to improve operational efficiency and reduce costs, we completed the divestiture of TA&T in February 2025, as discussed in Note 2 to the condensed consolidated financial statements. Additionally, in October 2025, we entered into a sublease agreement for the SINTX Armor facility, which is expected to generate approximately $1.0 million in savings over the sublease term, as discussed in Note 12 to the condensed consolidated financial statements.
Previous wording
As discussed in Note 9 to the condensed consolidated financial statements, in October 2025, we entered into the 2025 ATM Agreement to sell shares of our common stock from time to time, through an “at the market offering” program, having an aggregate offering price of $6.4 million. Through June 30, 2026, we have sold $1.3 million under the ATM, leaving a remaining balance of $5.1 million available under the ATM. Sales under the ATM depend on market conditions, eligibility to use the registration statement, trading volume and compliance with applicable offering limitations.
Current wording
We have also undertaken several financing and working capital initiatives to support our liquidity needs. In October 2025, we entered into the 2025 ATM Agreement, providing for the sale of up to $6.4 million of our common stock through an at-the-market offering program. Through September 30, 2026, we had sold approximately $1.4 million under the program, leaving approximately $5.0 million of remaining offering capacity, subject to market conditions, registration statement eligibility, trading volume, and applicable offering limitations. In June 2026, we entered into securities purchase agreements resulting in aggregate gross proceeds of approximately $4.5 million, as discussed in Note 9 to the condensed consolidated financial statements.
Previous wording
Despite the actions undertaken by management to improve liquidity and operating costs—including the divestiture of non-core operations, implementation of cost and pricing improvement initiatives, commercialization of newly cleared medical products, access to capital through our ATM program, and execution of the Armor facility sublease—management has concluded that substantial doubt remains regarding our ability to continue as a going concern for a period of at least 12 months from the date these condensed consolidated financial statements are issued. Our ability to continue as a going concern will depend on our ability to generate increased revenues, achieve profitability, obtain additional financing, and successfully execute our strategic business objectives. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
Current wording
Despite the actions undertaken by management to improve liquidity and operating costs—including increased commercial activity, cost and pricing improvement initiatives, commercialization of newly cleared medical products, equity financing activities, proceeds from warrant exercises subsequent to quarter-end, and other working capital initiatives—management has concluded that substantial doubt remains regarding our ability to continue as a going concern for a period of one year from the date these condensed consolidated financial statements are issued. Our ability to continue as a going concern will depend on our ability to generate increased revenues and operating cash flows, manage expenditures, obtain additional financing, and successfully execute our strategic business objectives. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
Previous wording
Net cash used in operating activities was $5.3 million during the six months ended June 30, 2026, compared to $3.7 million used during the same period in 2025, an increase of $1.6 million. The increase was primarily due to an increase in net loss of $0.9 million, combined with net outflow from the change in inventories of $1.4 million, other liabilities of $0.8 million, and accounts receivable of $0.2 million. These changes were partially offset by net inflow from the change in accounts payable and accrued expenses of $1.5 million and non-cash adjustments of $0.2 million.
Current wording
Net cash used in operating activities was $6.6 million during the nine months ended September 30, 2026, compared to $6.2 million used during the same period in 2025, an increase of $0.4 million. The increase was primarily due to outflow from the change in inventories of $1.6 million, non-cash adjustments of $0.6 million, and prepaid expenses and other current assets of $0.4 million. These changes were partially offset by net inflow from the decrease in net loss of $1.0 million, combined with changes in accounts payable and accrued expenses of $1.0 million, and accounts receivable of $0.2 million.
Previous wording
Net cash used in investing activities was $0.1 million during the six months ended June 30, 2026, compared to net cash provided by investing activities of $0.3 million during the same period in 2025, a decrease of $0.4 million, primarily due to a decrease in proceeds from sale of property and equipment.
Current wording
Net cash used in investing activities was $0.2 million during the nine months ended September 30, 2026, compared to net cash provided by investing activities of $1.0 million during the same period in 2025, a decrease of $1.2 million, primarily due to a decrease in proceeds from the acquisition of Sinaptic and the sale of property and equipment.
Previous wording
Net cash provided by financing activities was $4.8 million during the six months ended June 30, 2026, compared to $4.1 million provided during the same period in 2025. The $0.7 million increase was primarily due to an increase in proceeds from issuance of common stock in connection with ATM of $0.8 million, a decrease in repurchases of common stock into treasury of $0.1 million, and a decrease in payment on debt of $0.1 million. These changes were partially offset by a decrease in proceeds from issuance of common stock and warrants of $0.3 million.
Current wording
Net cash provided by financing activities was $4.7 million during the nine months ended September 30, 2026, compared to $7.9 million provided during the same period in 2025. The $3.2 million decrease was primarily due to a decrease in proceeds from issuance of common stock in connection with exercise of warrants in the prior year of $3.6 million, and a decrease in proceeds from issuance of common stock and prefunded warrants of $0.4 million. These changes were partially offset by an increase in proceeds from issuance of common stock in connection with ATM of $0.9 million, and a decrease in repurchases of common stock into treasury of $0.1 million.
Previous wording
A summary of our significant accounting policies and estimates is discussed in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes to those policies for the three and six months ended June 30, 2026.
Current wording
A summary of our significant accounting policies and estimates is discussed in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes to those policies for the three and nine months ended September 30, 2026.
Rearranged previous paragraphs (1)
Previous report — wording carried elsewhere
As discussed in Note 9 to the condensed consolidated financial statements, in June 2026, we entered into securities purchase agreements for aggregate proceeds of approximately $4.5 million.